清肺补肺汤联合奥马珠单抗对过敏性哮喘患者免疫功能与肺功能的影响

目的 探讨清肺补肺汤联合奥马珠单抗治疗过敏性哮喘的临床效果及对免疫功能及肺功能的影响。方法 选取榆阳区人民医院2018年8月到2021年8月收治的80例过敏性哮喘患者作为研究对象,随机分为对照组与研究组,各40例。对照组采用奥马珠单抗治疗,研究组在对照组的基础上采用中药清肺补肺汤联合治疗。比较两组患者的临床疗效,治疗前后中医证候积分、肺功能指标与免疫功能指标的变化以及药物不良反应。结果 治疗后,研究组总有效率为97.50%,对照组总有效率为77.50%,差异有统计学意义（P<0.05）;两组患者咳嗽、咯痰、喘息以及哮鸣音症状等中医证候积分明显降低,且研究组低于对照组,差异有统计学意义（P<0.05）;治疗1、3个月后两组患者肺功能指标均有提升,且研究组高于对照组（P<0.05）;治疗1、3个月后两组患者CD4⁺、CD3⁺、CD4⁺/CD8⁺T淋巴细胞免疫指标均有提升,且研究组高于对照组（P<0.05）;治疗后研究组不良反应率均低于对照组（P<0.05）。结论 清肺补肺汤联合奥马珠单抗治疗过敏性哮喘临床效果显著,可明显减轻临床症状,有效提升肺功能指标,增强免疫力,且安全性较高。

Qingfei Bufei Decoction combined with omalizumab in the treatment of allergic asthma and its effect on immune function and lung function

Objective To explore the clinical effect of Qingfei Bufei Decoction combined with omalizumab on allergic asthma, and its effect on immune function and lung function.Methods 80 patients with allergic asthma treated in Yuyang District People's Hospital from August 2018 to August 2021 were randomly divided into control group and study group, with 40 cases in each group. The control group was treated with omalizumab, and on the basis of the control group, the study group was treated with Qingfei Bufei Decoction. The clinical efficacy, changes of traditional Chinese medicine（TCM） syndrome score, pulmonary function index and immune function index before and after treatment, and adverse drug reactions were compared between the two groups.Results After treatment, the total effective rate was 97.50% in the study group and 77.50% in the control group, and the difference was statistically significant （P<0.05）. The scores of TCM syndrome such as cough, expectoration, wheezing and wheezing symptoms in the two groups were significantly reduced, and the study group was lower than the control group, and the differences were statistically significant （P<0.05）. The pulmonary function indexes of the two groups were improved at 1 and 3 months after treatment, and the study group was higher than the control group （P<0.05）. At 1 month and 3 months after treatment, CD4⁺, CD3⁺ and CD4⁺/ CD8⁺ T lymphocyte immune indexes of the two groups were increased, and the study group was higher than the control group （P<0.05）. After treatment, the adverse reaction rate of the study group was lower than that of the control group （P<0.05）.Conclusion Qingfei Bufei Decoction combined with omalizumab has significant clinical effect in the treatment of allergic asthma. It can significantly reduce clinical symptoms, effectively improve lung function indexes, improve patient immunity, and has high safety.